Physician profile
Lia E Perez
NPI 1891718607
$3,263.55
in general payments reported to CMS, 2019-2025
15 companies · $859 in 2025
The $859 reported for 2025 was less than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $366 · 2020: $186 · 2021: $356 · 2022: $268 · 2023: $277 · 2024: $952 · 2025: $859.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,088.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,088.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $775.14 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $471.93 | 2024-2025 | Rezlidhia, Tavalisse, Gavreto |
| Celgene Corporation | $334.28 | 2019-2025 | Breyanzi |
| Janssen Biotech, INC. | $319.71 | 2019-2023 | Imbruvica |
| Astrazeneca Pharmaceuticals Lp | $235.42 | 2021 | |
| Abbvie INC. | $213.46 | 2023-2024 | |
| Stemline Therapeutics INC. | $198.94 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $150.92 | 2022-2024 | |
| Genmab U.S., INC. | $125.00 | 2024 | Epkinly |
| Tg Therapeutics, INC. | $120.30 | 2021 | |
| Seagen INC. | $113.44 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $90.62 | 2019 | |
| Beigene USA, INC. | $78.00 | 2024 | Brukinsa |
| Pierre Fabre Pharmaceuticals, INC. | $36.39 | 2025 | Hemangeol |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lia Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.